Citadel Advisors
XTNT icon

Citadel Advisors’s Xtant Medical Holdings XTNT Stock Holding History

Citadel Advisors’s Portfolio XTNT Stock Details XTNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$80.6K Buy
191,369
+30,358
+19% +$14.6K ﹤0.01% 12842
2026
Q1 		$89.8K Sell
161,011
-126,787
-44% -$78K ﹤0.01% 12101
2025
Q4 		$226K Buy
287,798
+207,721
+259% +$151K ﹤0.01% 10776
2025
Q3 		$52K Buy
80,077
+13,369
+20% +$8.43K ﹤0.01% 12185
2025
Q2 		$49.3K Sell
66,708
-27,407
-29% -$15.6K ﹤0.01% 11772
2025
Q1 		$44.2K Buy
+94,115
New +$49.6K ﹤0.01% 12433
2024
Q4 		– Sell
-79,356
Closed -$53.6K – 15510
2024
Q3 		$53.6K Buy
79,356
+3,909
+5% +$2.58K ﹤0.01% 11827
2024
Q2 		$47.5K Buy
75,447
+9,994
+15% +$7.97K ﹤0.01% 11819
2024
Q1 		$76.6K Buy
65,453
+5,587
+9% +$6.13K ﹤0.01% 11709
2023
Q4 		$67.6K Buy
59,866
+28,105
+88% +$33K ﹤0.01% 11425
2023
Q3 		$34.9K Buy
31,761
+4,652
+17% +$4.99K ﹤0.01% 12151
2023
Q2 		$25.2K Buy
27,109
+4,606
+20% +$3.07K ﹤0.01% 12534
2023
Q1 		$14.3K Sell
22,503
-21,155
-48% -$15.4K ﹤0.01% 13317
2022
Q4 		$28.8K Buy
+43,658
New +$28.5K ﹤0.01% 12790
2021
Q3 		– Sell
-36,531
Closed -$60K – 14786
2021
Q2 		$60K Sell
36,531
-55,442
-60% -$98.6K ﹤0.01% 13253
2021
Q1 		$217K Buy
91,973
+24,917
+37% +$53.2K ﹤0.01% 11539
2020
Q4 		$80K Buy
+67,056
New +$86.3K ﹤0.01% 10345
2018
Q1 		– Sell
-1,138
Closed -$8K – 8866
2017
Q4 		$8K Buy
+1,138
New +$8.97K ﹤0.01% 7901
2017
Q1 		– Sell
-3,913
Closed -$26K – 8131
2016
Q4 		$26K Buy
3,913
+2,390
+157% +$20.6K ﹤0.01% 7027
2016
Q3 		$21K Buy
+1,523
New +$28K ﹤0.01% 7032
2014
Q2 		– Sell
-420
Closed -$42K – 8357
2014
Q1 		$42K Buy
420
+266
+173% +$21K ﹤0.01% 6891
2013
Q4 		$9K Buy
+154
New +$9.84K ﹤0.01% 6735

Other funds holding XTNT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Citadel Advisors's XTNT Position: Q2 2026 in Review

Citadel Advisors increased its Xtant Medical Holdings (XTNT) stake by 19% in Q2 2026, buying an estimated $14.6K and bringing the position to 191,369 shares worth $80.6K. The position accounts for ﹤0.01% of the portfolio, ranked #12842.

Citadel Advisors first reported a position in XTNT in Q4 2013 and has held it in 22 quarters since. The position peaked at $226K in Q4 2025. 32 funds tracked by Wall St. Rank hold XTNT as of Q2 2026.

  • Citadel Advisors held 191,369 shares of Xtant Medical Holdings worth $80.6K as of Q2 2026.
  • Citadel Advisors bought 30,358 Xtant Medical Holdings shares in Q2 2026, an estimated $14.6K.
  • Xtant Medical Holdings made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12842 holding.
  • Citadel Advisors first reported a position in Xtant Medical Holdings in Q4 2013 and has held it in 22 quarters since.
  • Citadel Advisors's Xtant Medical Holdings position peaked at $226K in Q4 2025.
  • 32 funds tracked by Wall St. Rank held Xtant Medical Holdings as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.